ClinicalTrials.gg
RecruitingNCT07210710CARESUpdated Oct 9, 2026

CKD Awareness, Referrals, Education, and Support Intervention for Early-Stage CKD

An interventional study of CKD Awareness, Referrals, Education, and Support (CARES) and Attention control in Chronic Kidney Disease and Diabetes, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 9, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
472nd of 819
50 · median 72
Started
2025
with 56 others
No phase
314 of 988
62 open now
Primary completion
2026-12
later than 43 of 213 live
Registered
925th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 472nd largest by planned enrollment of the 819 interventional ones that give a count, is one of 57 that started in 2025, is one of 314 with no phase, reaches primary completion later than 43 of the 213 other live ones, and was the 925th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to learn if an intervention delivering education, motivational support, and social support can prevent worsening kidney disease in adults with diabetes and early-stage kidney disease. The main questions it aims to answer are:

  1. Is this intervention feasible to deliver and acceptable to patients?
  2. What is the impact of the intervention on patient motivation, self-efficacy, kidney disease knowledge, and use of support services referrals?

The investigators will compare information collected about participants' response to this intervention with a group of similar patients who receive general diabetes information.

Participants will meet virtually with a nurse approximately 1 week before a scheduled primary care provider visit and complete surveys over the phone three times in a period of three months.

Read the detailed description

Chronic kidney disease (CKD) progression to kidney failure causes devastating declines in quality of life and mortality, with high healthcare costs. CKD affects \~15% of all adults in the U.S. and \~40% of adults with diabetes, with substantial variability in rate of progression to kidney failure. Negative social determinants of health (SDOH), such as food insecurity can speed up disease progression. However, if CKD progression to kidney failure can be prevented or delayed, patients can experience minimal impact on health and well-being. The diagnosis, treatment, and monitoring of early-stage, asymptomatic CKD occurs predominantly in the primary care setting, including for those with diabetes. Unfortunately, the rates of guideline-based CKD care delivery are low, and as a result, clinical diagnosis of early-stage CKD is as low as 50%. Delay in receiving a CKD diagnosis is associated with faster progression to kidney failure. Furthermore, because CKD is not always prioritized in the busy primary care setting, most patients are unaware they have CKD and have low rates of CKD knowledge, which impedes their ability to adhere to treatment. To address the issues of underdiagnosis, patients' lack of disease knowledge and self-efficacy, and the impact of SDOH for patients with diabetes and CKD, proactive action is critical. The investigators will target patients with diabetes who are eligible for an early-stage CKD diagnosis with a nurse-led, pre-primary care-visit 1:1 virtual session including evidence-based CKD education, motivational interviewing, and SDOH screening with referrals to services.

03

Conditions studied

  • Chronic Kidney Disease
  • Diabetes

Keywords

  • chronic kidney disease
  • diabetes
  • chronic disease self-management
  • disease awareness
  • intervention
  • social determinants of health
  • motivation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults (18+)
  • diabetes diagnosis (type 1 or 2)
  • CKD Stage 3 diagnosis eligible
  • >1 prior visit at the UIHealth primary care clinics
  • can speak English

Exclusion criteria

Exclusion Criteria:

  • CKD of congenital or pediatric onset
  • history of kidney transplant
  • cognitive impairment as documented in the medical record
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants will participate in a nurse-led virtual session delivering education about chronic kidney disease, motivational interviewing to set a self-management goal, and screening/referral for social determinants of health barriers to treatment adherence and engagement.

    Behavioral: CKD Awareness, Referrals, Education, and Support (CARES)

  • Active comparator
    Control group

    The attention control group will participate in a nurse-led virtual session delivering general information about diabetes and treatment.

    Behavioral: Attention control

Interventions

  • BehavioralCKD Awareness, Referrals, Education, and Support (CARES)

    We will target diabetic patients eligible for an early-stage CKD diagnosis with a nurse-delivered, pre-PCP-visit 1:1 virtual session including 1) tailored, evidence-based CKD education 2) motivational interviewing with self-management goal setting, and 3) social determinants of health screening with referrals to services as needed.

  • BehavioralAttention control

    The control group will receive an attention control session of general education about diabetes-related health behaviors (e.g., diet and physical activity) that does not refer to CKD, based on American Diabetes Association materials.

06

What researchers measure

Primary outcomes

  1. Motivation for diabetes-related self-care behaviour scale

    Participant self-report. A scale from 1-5, with a lower score meaning not motivated and a higher score meaning highly motivated. Items are different self-management behaviors (e.g., medication, diet, exercise).

    Time frame: From enrollment to study completion (2-3 months)

  2. Kidney Disease Knowledge Survey

    Participant self-report. A set of fact-based questions about kidney disease which has a right and a wrong answer. Participants will be scored based on % correct answers.

    Time frame: From enrollment to study completion (2-3 months)

  3. CKD Self Efficacy Instrument

    Participant self-report. The scale ranges from 1-10, with low scores indicating not at all confident and high scores indicating totally confident.

    Time frame: From enrollment to study completion (2-3 months)

  4. Social referral uptake

    Participant self-report of uptake of any support services for barriers to treatment adherence that are needed.

    Time frame: From enrollment to study completion (2-3 months)

Secondary outcomes

  1. Brief Illness Perceptions Questionnaire

    Participant self-report. Scale from 1-10, with the meaning of numbers changing per item. Assessing participants' perspective and understanding of their chronic condition. Items assessed individually or using clustering approaches.

    Time frame: From enrollment to study completion (2-3 months)

  2. Patient activation Measure

    Participant self-report. Scales are 1-4 with a not applicable option, lower scores meaning less activated and engaged in care and higher scores meaning more activated and engaged in care.

    Time frame: From enrollment to study completion (2-3 months)

  3. PROMIS Medication Adherence Scale

    Participant self-report. Scale from 1-5 indicating agree to disagree, with items about performance of medication adherence behaviors.

    Time frame: From enrollment to study completion (2-3 months)

  4. Dialysis Diet and Fluid Non-adherence Questionnaire

    Participant self-report. One item asking how many days in the last week guidelines were not followed, and another item asking to what degree they were not followed, from completely to not at all.

    Time frame: From enrollment to study completion (2-3 months)

  5. International Physical Activity Questionnaire

    Participant self-report. Scale is 1-7 indicating the number of days a type of physical activity was performed in the previous week. Items are different types of physical activity behaviors.

    Time frame: From enrollment to study completion (2-3 months)

  6. Care plan changes

    review of EHR data related to PCP visit, assess if any CKD-related information or changes were documented

    Time frame: From enrollment to study completion (2-3 months)

  7. Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences

    Participant self-report. Items and response options vary and ask questions about social determinants of health issues (e.g., food insecurity, housing insecurity). Screening tool with no scores.

    Time frame: From enrollment to study completion (2-3 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data collected from participants includes: demographic, clinical history characteristics, comorbidity data, and new diagnoses or treatment plan changes will be collected through electronic medical record (EMR) abstraction. Social determinants of health barriers and uptake, self-efficacy, patient activation, motivation, treatment adherence, CKD knowledge, and CKD perceptions, feasibility, and acceptability quantitative data will be acquired through self-report questionnaires. All data will be collected in REDCap and de-identified prior to receipt by the repository, and a unique study identifier will be created for each subject. All deidentified quantitative study data that are not designated as restricted use by our repository, INtellectual property in DIGital form available online in an Open environment (INDIGO), will be shared openly.

Time frame: All data will be shared the end of the award period or the time of an associated publication, whichever comes first. Publication-specific data will be shared when the pre-print is available. A DOI will aid in findability and the DOI will be included in relevant publications whenever possible. Study data deposited in INDIGO will be available to the research community in perpetuity.

Access criteria: Users of the public use data must register with INDIGO and agree to the Terms of Use, which are designed to protect study participants by limiting data use to scientific research and aggregate statistical reporting, prohibiting attempts to identify study participants, and requiring immediate reporting of any disclosure of study participant identity. Data users also agree not to share or redistribute any data downloads.

Data sharing details ↗ · indigo.uic.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 13 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2026 → Dec 2026 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Oct 7, 2025
StartActual
Nov 15, 2025
Primary completionEst.
Dec 30, 2026was Apr 2026
CompletionEst.
Jul 31, 2027was Jul 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
1 site added — first site in United States
Show site
  • University of Illinois Chicago Hospital · Chicago, United States
Oct 9, 2026
Primary completion
Apr 30, 2026→Dec 30, 2026
Oct 9, 2026
Study completion
Jul 31, 2026→Jul 31, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • University of Illinois Chicago Hospital · Chicago, United States
    Primary completion Apr 30, 2026→Dec 30, 2026
    Study completion Jul 31, 2026→Jul 31, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07210710
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Nov 15, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion